Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Akari Therapeutics ADR (AKTX)

Akari Therapeutics ADR (AKTX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 75,267
  • Shares Outstanding, K 51,908
  • Annual Sales, $ 0 K
  • Annual Income, $ -17,080 K
  • 60-Month Beta 1.26
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 6.16
Trade AKTX with:

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.3200 +9.85%
on 12/30/21
1.6399 -11.58%
on 12/23/21
-0.0600 (-3.97%)
since 12/14/21
3-Month
1.3200 +9.85%
on 12/30/21
1.8294 -20.74%
on 10/22/21
-0.1900 (-11.59%)
since 10/14/21
52-Week
1.3200 +9.85%
on 12/30/21
4.2100 -65.56%
on 02/22/21
-1.0900 (-42.91%)
since 01/14/21

Most Recent Stories

More News
Akari Therapeutics to Present at H.C. Wainwright BioConnect Virtual Conference

NEW YORK and LONDON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on...

AKTX : 1.4500 (-1.37%)
Akari Therapeutics, Plc Announces $6.0 Million Registered Direct Offering

NEW YORK and LONDON, Dec. 30, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX) (“Akari” or the “Company”), a biopharmaceutical company...

AKTX : 1.4500 (-1.37%)
Akari Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Clinical Progress

Sites opened in Phase III study of nomacopan in bullous pemphigoid (BP)Phase III study of nomacopan in severe pediatric hematopoietic stem cell...

AKTX : 1.4500 (-1.37%)
Akari Therapeutics Announces New Data with Nomacopan from its Surface of the Eye Program

Nomacopan eyedrops reduced inflammation more than both standard treatments cyclosporin and the steroid dexamethasone in a model of allergic eye...

AKTX : 1.4500 (-1.37%)
Akari Therapeutics to Present at the Cantor Virtual Global Healthcare Conference

NEW YORK and LONDON, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and...

AKTX : 1.4500 (-1.37%)
Akari Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Clinical Progress

NEW YORK and LONDON, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and...

AKTX : 1.4500 (-1.37%)
Akari Therapeutics to Present Its Phase III Plans for Nomacopan in Patients with Bullous Pemphigoid at the 2021 International Pemphigus & Pemphigoid Foundation (IPPF) Scientific Symposium

NEW YORK and LONDON, Sept. 10, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and...

AKTX : 1.4500 (-1.37%)
Akari Therapeutics to Present at the H.C. Wainwright Global Investment Conference

NEW YORK and LONDON, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and...

AKTX : 1.4500 (-1.37%)
Akari Therapeutics Announces Private Placement

NEW YORK and LONDON, July 07, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX) (“Akari” or the “Company”), a biopharmaceutical company focused on innovative therapeutics to...

AKTX : 1.4500 (-1.37%)
Akari Therapeutics Reports Q1 2021 Financial Results and Highlights Recent Clinical Progress

NEW YORK and LONDON, June 29, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and...

AKTX : 1.4500 (-1.37%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Akari Therapeutics PLC is a biopharmaceutical company. It focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases. The Company's lead drug consist of Coversin is a recombinant small protein, which acts on complement component-C5,...

See More

Key Turning Points

3rd Resistance Point 1.5167
2nd Resistance Point 1.5033
1st Resistance Point 1.4767
Last Price 1.4500
1st Support Level 1.4367
2nd Support Level 1.4233
3rd Support Level 1.3967

See More

52-Week High 4.2100
Fibonacci 61.8% 3.1060
Fibonacci 50% 2.7650
Fibonacci 38.2% 2.4240
Last Price 1.4500
52-Week Low 1.3200

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar